Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadine Tuaillon

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Investigative Ophthalmology & Visual Science|June 30, 2004
Endotoxin-induced uveitis in cyclooxygenase-2-deficient miceJingsheng Tuo, Nadine Tuaillon, DeFen Shen, et al.
Ophthalmology|February 13, 2003
Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphomaChi-Chao Chan, DeFen Shen, Joseph J Hackett, et al.
Immunological Investigations|November 8, 2003
Effect of sex hormones on experimental autoimmune uveoretinitis (EAU)Ronald R Buggage, Dawn M Matteson, De Fen Shen, et al.
Investigative Ophthalmology & Visual Science|May 1, 2002
MCP-1 expression in endotoxin-induced uveitisNadine Tuaillon, De Fen Shen, Ravi B Berger, et al.
Advances in Enzyme Regulation|January 8, 2008
Enhancing the potency of therapeutic monoclonal antibodies via Fc optimizationJeffrey B Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 26, 2011
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic miceMeghan M Flaherty, Timothy K MacLachlan, Misty Troutt, et al.
Cancer Research|September 19, 2007
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptorsJeffrey B Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, et al.
Blood|June 8, 2006
CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphomaChristopher T Rankin, Maria-Concetta Veri, Sergey Gorlatov, et al.
Journal of Molecular Biology|April 13, 2010
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletionSyd Johnson, Stephen Burke, Ling Huang, et al.
Arthritis and Rheumatism|May 28, 2010
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffoldMaria-Concetta Veri, Stephen Burke, Ling Huang, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Investigative Ophthalmology & Visual Science|June 30, 2004
Endotoxin-induced uveitis in cyclooxygenase-2-deficient miceJingsheng Tuo, Nadine Tuaillon, DeFen Shen, et al.
Ophthalmology|February 13, 2003
Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphomaChi-Chao Chan, DeFen Shen, Joseph J Hackett, et al.
Immunological Investigations|November 8, 2003
Effect of sex hormones on experimental autoimmune uveoretinitis (EAU)Ronald R Buggage, Dawn M Matteson, De Fen Shen, et al.
Investigative Ophthalmology & Visual Science|May 1, 2002
MCP-1 expression in endotoxin-induced uveitisNadine Tuaillon, De Fen Shen, Ravi B Berger, et al.
Advances in Enzyme Regulation|January 8, 2008
Enhancing the potency of therapeutic monoclonal antibodies via Fc optimizationJeffrey B Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 26, 2011
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic miceMeghan M Flaherty, Timothy K MacLachlan, Misty Troutt, et al.
Cancer Research|September 19, 2007
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptorsJeffrey B Stavenhagen, Sergey Gorlatov, Nadine Tuaillon, et al.
Blood|June 8, 2006
CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphomaChristopher T Rankin, Maria-Concetta Veri, Sergey Gorlatov, et al.
Journal of Molecular Biology|April 13, 2010
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletionSyd Johnson, Stephen Burke, Ling Huang, et al.
Arthritis and Rheumatism|May 28, 2010
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffoldMaria-Concetta Veri, Stephen Burke, Ling Huang, et al.
Pageof 1